SeaStar Medical Secured $3.3 Million in Warrant Exercise

The company entered agreements to exercise warrants at a reduced price, raising capital for general business needs.

Updated on Oct. 5, 2026 in Healthcare

Isometric editorial illustration of a brass stamp and a heavy steel vault lock, representing institutional financial security. — SeaStar Medical raised approximately $3.3 million in gross proceeds through an agreement to exercise outstanding warrants at a reduced price. AI Illustration. Upload story photo >

Live Poll

Do you trust companies that frequently use warrant exercises to raise capital?

SeaStar Medical has entered into agreements for the exercise of outstanding warrants, resulting in approximately $3.3 million in gross proceeds. The company will issue new unregistered warrants to purchase 1,708,004 common shares as part of the transaction.

Why it matters

This capital injection provides the company with additional working capital to support ongoing corporate operations. By incentivizing the exercise of existing warrants, the company can strengthen its liquidity position outside of traditional equity offerings.

The agreement covers the exercise of 854,002 shares at a price of $3.866 per share, generating $3.3 million in gross proceeds. Additionally, SeaStar Medical will issue 1,708,004 new warrants with an exercise price of $3.616 per share.

The players

SeaStar Medical

This is a medical technology company based in Denver that focuses on developing extracorporeal therapies to reduce hyperinflammation.

H.C. Wainwright & Co.

This investment bank serves as a financial advisor and placement agent for corporate offerings and institutional capital raises.

The details

Investors agreed to exercise warrants initially issued between June and August 2025 at a reduced price in exchange for new unregistered warrants. The transaction was facilitated by H.C. Wainwright & Co., and the firm must now file a resale registration statement with the SEC.

Prior warrants were issued between June and August 2025.
Definitive agreements for the exercise were reached on October 2, 2026.
The offering is expected to close on or about October 5, 2026.
A resale registration statement is required by November 1, 2026.

Market Landscape

This move reflects a broader trend of small-cap healthcare firms utilizing warrant exercises to bolster balance sheets in a tight capital market. It positions SeaStar Medical to maintain operations by leveraging existing investor relationships rather than seeking dilutive traditional financing.

For shareholders, this transaction results in the issuance of over 2.5 million new potential common shares through the exercise of old and new warrants. This increase in the total share count may impact future earnings per share calculations for retail investors.

The takeaway

This transaction allows the company to secure immediate funding by incentivizing current warrant holders to convert their holdings. Investors should monitor how the company allocates these funds toward its development pipeline in upcoming quarterly reports.